68Ga-PSMA-11 is recommended for the selection of patients for treatment in the package insert for 177Lu-PSMA-617. We aimed to compare imaging properties and post-treatment outcomes from radioligand therapy (RLT) of patients selected with 68Ga-PSMA-11 and 18F-DCFPyL.
We retrospectively evaluated 80 patients undergoing PSMA RLT, who had pretreatment imaging using either 68Ga-PSMA-11 or 18F-DCFPyL. For both groups, we compared the biodistribution and lesion uptake and the PSA response to treatment.
Both agents had comparable biodistribution. Patients initially imaged with 18F-DCFPyL had a higher PSA response (66% vs. 42%), and more patients had a PSA50 response (72% vs. 43%) compared to patients imaged with 68Ga-PSMA-11.
18F-DCFPyL and 68Ga-PSMA-11 had comparable biodistribution and lesion uptake. Patients imaged with 18F-DCFPyL demonstrated clinical benefit to PSMA RLT comparable to those imaged with 68Ga-PSMA-11, and either agent can be used for screening patients.
Frontiers in oncology. 2024 Jun 27*** epublish ***
Surekha Yadav, Sarasa T Kim, Abuzar Moradi Tuchayi, Fei Jiang, Amanda Morley, Rachelle Saelee, Yingbing Wang, Roxanna Juarez, Courtney Lawnh-Heath, Vadim S Koshkin, Thomas A Hope
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States., Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, United States., Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States.